HN2011002095A - [1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa. - Google Patents

[1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa.

Info

Publication number
HN2011002095A
HN2011002095A HN2011002095A HN2011002095A HN2011002095A HN 2011002095 A HN2011002095 A HN 2011002095A HN 2011002095 A HN2011002095 A HN 2011002095A HN 2011002095 A HN2011002095 A HN 2011002095A HN 2011002095 A HN2011002095 A HN 2011002095A
Authority
HN
Honduras
Prior art keywords
methods
kinase inhibitors
pridins
triazolo
compounds
Prior art date
Application number
HN2011002095A
Other languages
English (en)
Spanish (es)
Inventor
Caroline Leriche
Eric Auclair
Roux Jacques Le
David N Middlemiss
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42229029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2011002095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of HN2011002095A publication Critical patent/HN2011002095A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HN2011002095A 2009-02-13 2011-07-29 [1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa. HN2011002095A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09360013 2009-02-13

Publications (1)

Publication Number Publication Date
HN2011002095A true HN2011002095A (es) 2014-01-06

Family

ID=42229029

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011002095A HN2011002095A (es) 2009-02-13 2011-07-29 [1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa.

Country Status (24)

Country Link
US (1) US20120041195A1 (enExample)
EP (1) EP2396324A1 (enExample)
JP (1) JP2012517971A (enExample)
KR (1) KR20110116160A (enExample)
CN (1) CN102317288A (enExample)
AR (1) AR075411A1 (enExample)
BR (1) BRPI1008850A2 (enExample)
CA (1) CA2751517A1 (enExample)
CL (1) CL2011001947A1 (enExample)
CO (1) CO6420343A2 (enExample)
CR (1) CR20110386A (enExample)
DO (1) DOP2011000248A (enExample)
EA (1) EA201101188A1 (enExample)
EC (1) ECSP11011250A (enExample)
HN (1) HN2011002095A (enExample)
IL (1) IL214426A0 (enExample)
MX (1) MX2011008549A (enExample)
NI (1) NI201100151A (enExample)
NZ (1) NZ594508A (enExample)
PE (1) PE20120110A1 (enExample)
SG (1) SG173610A1 (enExample)
TN (1) TN2011000379A1 (enExample)
WO (1) WO2010092041A1 (enExample)
ZA (1) ZA201105896B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120044966A (ko) 2009-06-05 2012-05-08 세파론, 인코포레이티드 1,2,4-트리아졸로〔1,5ａ〕 피리딘 유도체의 제조 및 용도
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
AR081960A1 (es) * 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
MA35049B1 (fr) 2011-04-21 2014-04-03 Bayer Ip Gmbh Triazolopyridines
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
KR20130091464A (ko) 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
WO2013135612A1 (en) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
CN104603136B (zh) 2012-07-10 2017-06-27 拜耳医药股份有限公司 制备取代的三唑并吡啶的方法
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
LT3008062T (lt) 2013-06-11 2017-06-12 Bayer Pharma Aktiengesellschaft Pakeistųjų triazolpiridinų provaistų dariniai
EP4063371A1 (en) * 2019-11-22 2022-09-28 Medshine Discovery Inc. Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
CA2386955A1 (en) 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
EP1575959B1 (en) * 2002-12-18 2010-07-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
WO2005037285A1 (en) 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2600531A1 (en) 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
JP5079500B2 (ja) 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
JP2008543775A (ja) 2005-06-08 2008-12-04 ターゲジェン インコーポレーティッド 眼の障害を治療するための方法および組成物
JP2009531274A (ja) * 2005-12-07 2009-09-03 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド キナーゼ阻害性ピロロピリジン化合物
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
WO2008025821A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
BRPI0718162A2 (pt) * 2006-10-20 2013-11-26 Irm Llc Composição e métodos para modulara os receptores c-kit e pdgfr
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
CA2673003A1 (en) 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
BRPI0909945A2 (pt) * 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
US20100048557A1 (en) * 2008-06-20 2010-02-25 Bing-Yan Zhu Triazolopyridine JAK Inhibitor Compounds and Methods
WO2010010189A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010018874A1 (en) * 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法

Also Published As

Publication number Publication date
CO6420343A2 (es) 2012-04-16
IL214426A0 (en) 2011-09-27
NZ594508A (en) 2013-12-20
ECSP11011250A (es) 2011-10-31
BRPI1008850A2 (pt) 2016-03-15
SG173610A1 (en) 2011-09-29
CN102317288A (zh) 2012-01-11
KR20110116160A (ko) 2011-10-25
CL2011001947A1 (es) 2012-03-16
NI201100151A (es) 2012-10-03
US20120041195A1 (en) 2012-02-16
EA201101188A1 (ru) 2012-04-30
EP2396324A1 (en) 2011-12-21
DOP2011000248A (es) 2011-10-31
AR075411A1 (es) 2011-03-30
MX2011008549A (es) 2011-12-06
CR20110386A (es) 2011-12-02
ZA201105896B (en) 2012-03-28
PE20120110A1 (es) 2012-02-20
JP2012517971A (ja) 2012-08-09
WO2010092041A1 (en) 2010-08-19
CA2751517A1 (en) 2010-08-19
TN2011000379A1 (en) 2013-03-27

Similar Documents

Publication Publication Date Title
HN2011002095A (es) [1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa.
ECSP22051489A (es) Compuestos inhibidores de metaloenzimas
HUE061909T2 (hu) Pirazolo[1,5-a]pirimidinek alkalmazása ATR kináz inhibítorként, rákos megbetegedések kezelésére
CO6940433A2 (es) Compuestos inhibidores de metaloenzimas
EA201171367A1 (ru) Винилиндазолильные соединения
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
WO2008124849A3 (en) Pyrrolo-pyridine kinase modulators
MX386224B (es) Activadores de cinasa de piruvato para su uso en terapia.
CU24396B1 (es) Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
UY37018A (es) Inhibidores bicíclicos de pad4
CR10995A (es) Inhibidores de la actividad de akt
JOP20140141B1 (ar) استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية
PH12013502622A1 (en) Metalloenzyme inhibitor compounds
CR20110368A (es) Compuestos de quinazolina sustituidos
MY162950A (en) Compounds and methods for kinase modulation, and indications therefor
WO2013077921A3 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
UY33931A (es) Agentes de union biespecificos
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
UY33985A (es) Sales de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
DK3134413T3 (da) Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer
UY32291A (es) Inhibidores de quinasa con perfiles de seguridad cyp mejorados